INTRODUCTION
The peptide transport system in the small intestine has physiological roles in the absorption of small peptides to maintain protein nutrition (7, 13, 19, 20) .
Moreover, the intestinal peptide transport system mediates the absorption of a broad range of peptide-like drugs, such as ß-lactam antibiotics, the anti-cancer agent bestatin, and angiotensin converting enzyme inhibitors, thereby playing an important pharmacological role for oral drug delivery (11, 34, 36) . Recently, cDNA encoding an oligopeptide transporter (PEPT1) was isolated from rabbit (4) , human (15), rat (25) and mouse (5) and its structural and functional characteristics have been elucidated. In addition, molecular identification of PEPT1 provides a novel opportunity to determine the mechanisms of its regulation. The activity of PEPT1 varies significantly in response to several factors. Several factors have been reported to up-regulate the activity of PEPT1 such as its own substrates (32, 35), diet (28), insulin (33), α 2 -adrenergic agonists (1) and the σ-receptor ligand (+)-pentazocine (6) . For these stimuli, the regulation of PEPT1 activity is considered to be at the level of gene expression, transport function or protein recruitment to the plasma membrane. On the other hand, it has been reported that cAMP (22) and protein kinase C activation (3) inhibited the activity of PEPT1. These inhibitory effects are likely to be due to post-transcriptional modifications involving phosphorylation/dephosphorylation of PEPT1. Therefore, the mechanism of down-regulation of PEPT1 at the level of expression has not been elucidated.
Thyroid hormone is secreted from the thyroid to maintain normal growth and development, normal body temperature, and normal energy levels. Most of its effects appear to be mediated by activation of nuclear receptors that lead to increased formation of mRNA and subsequent protein synthesis (24). Thyroid hormone has prominent effects on gastrointestinal development, structure and function. The absorption of various nutritional substrates from the small intestine was shown to be altered in response to thyroid state (14). As 3,5,3'-Ltriiodothyronine (T 3 ) is known to increase the metabolism of glucose, the effect of T 3 on the hexose transport systems in the small intestine (SGLT1, GLUT5) have been studied extensively (16, 17) . On the other hand, no information is available about the effects of T 3 on the absorption of oligopeptides, which are also important nutritional substrates.
To elucidate the effects of T 3 on the absorption of oligopeptides, we investigated the activity of PEPT1 by measuring [
14 C]glycylsarcosine uptake by a human intestinal epithelial cell line, Caco-2. Caco-2 cells are known to express PEPT1 and have been used to study the regulation of its activity and expression (1, 3, 22, 32, 33, 35 
Polyclonal antibodies against human PEPT1 and Western blot analysis.
Polyclonal antibodies were raised in rabbits against a synthetic peptide Statistical analysis. Data were analyzed statistically by nonpaired t-test or one-way ANOVA followed by Scheffé's test when multiple comparisons were needed. Probability values less than 5% were considered significant. nM T 3 for 4 days led to a decrease in PEPT1 mRNA content (25% of the control, P < 0.01) (Fig. 5B) . Therefore, it was suggested that the decrease in [ 14 C]glycylsarcosine transport activity was due to the decreased transcription of PEPT1 mRNA. The amount of GAPDH mRNA, which was used as an internal standard, was not changed significantly (P = 0.752) by this treatment (data not shown).
RESULTS

Effect
Human PEPT1 protein expression. To investigate the effect of T 3 on the expression of PEPT1 protein, apical membranes were purified from Caco-2 cells and were subjected to immunoblot analysis. A primary band of about 80 kDa was detected using affinity-purified anti-PEPT1 antibodies, which disappeared when In addition, the expression levels of PEPT1 mRNA and protein in Caco-2 cells were decreased by T 3 treatment. It was reported that treatment of thyroid hormone increased the expression of Na + /K + -ATPase α1 protein and did not change the expression of SGLT1 protein in Caco-2 cells (16). In addition, the uptake of α-methyl-D-glucoside and threonine was not decreased by T 3 treatment (Fig. 3) , suggesting that the expression of these transporters was not decreased.
Therefore, it seems likely that T 3 treatment does not lead to a general decrease in protein expression. This is the first study showing the hormonal down-regulation of PEPT1 expression. During the preparation of this manuscript, it was reported that expression of PEPT1 was decreased by epidermal growth factor treatment in
Caco-2 cells (23).
Thyroid hormone is responsible for optimal growth, development, function, and maintenance of all body tissues. In the small intestine, the processes (27) showed that expression levels of PEPT1 mRNA and protein were maximal 3-5 days after birth in the duodenum, jejunum and ileum, and then declined rapidly.
They suggested that this change in PEPT1 expression might be related to an adaptive response to changes in the diet, from high-protein milk to an adult diet containing more carbohydrate than protein. However, it was reported that the serum concentration of thyroid hormone rises from postnatal day 5 to 15 (8), at the same time as expression levels of PEPT1 decline (27). Therefore, it seems likely that thyroid hormone regulates the expression of PEPT1 during development. Further studies are required to determine the precise mechanism of developmental regulation of PEPT1 expression.
The mechanisms of action of thyroid hormone are quite diverse. Although thyroid hormone may exert its effects via a number of cellular loci, its major effect appears to be on transcriptional regulation of target genes. Thyroid hormone enters the cells and proceeds to the nucleus, where it binds to the thyroid hormone receptor (TR). The formation of ligand-bound TR complexes specifically interacting with thyroid hormone responsive elements located in regulatory regions of target genes is presumably a necessary first step for activation or suppression of target genes (37). In the present study, we demonstrated that T 3 treatment markedly decreased PEPT1 mRNA levels (Fig. 5) .
It is likely that the inhibition of [ 14 C]glycylsarcosine transport by T 3 is due to the inhibitory effect of T 3 on the transcription of PEPT1 mRNA. However, it is not yet known whether the inhibition of transcription of PEPT1 mRNA is due to a direct effect of T 3 on PEPT1 mRNA. Recently, promoter analyses of mouse and rat PEPT1 were reported (5, 28). These analyses revealed the putative nucleotide sequence upstream of the translation start site and the corresponding transcription factor. Thyroid hormone responsive elements were not found in the promoter regions of rat and mouse PEPT1 genes, although these may be differences among rat, mouse and human homologues. We have examined the effect of thyroid hormone on PEPT1 activity and expression in hyperthyroid rats and found that treatment of thyroid hormone decreased the activity of PEPT1 in rat small intestine (K. Ashida, T. Katsura, H. Saito, and K. Inui, unpublished observations).
Although the precise mechanism of the effect of T 3 on PEPT1 expression remains to be determined, it is possible that T 3 may act indirectly with PEPT1 mRNA in rat and human.
In conclusion, we demonstrated that the activity of PEPT1 is inhibited by Thereafter, the radioactivity of the solubilized cells was determined. Each column represents the mean ± S.E. of nine monolayers from three separate experiments. *P < 0.05, **P < 0.01, significantly different from control. 
